Clinical

Dataset Information

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)


ABSTRACT: An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.

DISEASE(S): Neuroendocrine Tumors,Gastroenteropancreatic Neuroendocrine Tumor,Pancreatic Neoplasms,Stomach Neoplasms,Intestinal Neoplasms

PROVIDER: 2233976 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR